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| INTRODUC TI ON
Direct oral anticoagulants (DOACs), such as apixaban and rivaroxaban, are designed to reduce the inconvenience of frequent monitoring during heparin and warfarin therapy. Apixaban and rivaroxaban are approved for the prevention and treatment of deep vein thrombosis (DVT), pulmonary embolism (PE), and embolic stroke in atrial fibrillation (AF) patients. 1, 2 Apixaban and rivaroxaban are direct factor Xa inhibitors. Peak plasma apixaban concentration is reached approximately three hours post-dose and its average elimination half-life is 12 hours. Apixaban has been reported to be safe and well tolerated following when administered as single doses of up to 50 mg in healthy subjects without a history of clinically relevant bleeding events. 4 Rivaroxaban is also absorbed rapidly and maximum plasma concentration is reached only 2-4 hours after single doses up to 80 mg, and in healthy young subjects, it is eliminated from plasma with a half-life of 5-9 hours. 5, 6 Both apixaban and rivaroxaban are eliminated in liver and kidneys. 4, 7 DOACs generally do not require routine monitoring because they have predictable pharmacokinetics and pharmacodynamics, but measurement of plasma DOAC level may be desired in special circumstances, such as, after a suspected overdose, in cases of renal or hepatic insufficiency, in the elderly, and in those with a low body weight. 4, 6, 8 Recently, the clinical administration of DOACs has increased rapidly in the contexts of stroke prevention in patients with AF and for the treatment of DVT and PE. Nonetheless, intracranial hemorrhage (0.5%) and fatal bleeding (0.2%) can occur in patients receiving DOACs. 9 No therapeutic ranges for DOACs have been published based on the results of clinical trials and potential interferences by clinical and laboratory parameters have not been well characterized. 10, 11 Manufacturers and previous reports provide only peak and/or trough plasma concentrations as determined by liquid chromatography/tandem mass spectrometry (LC-MS/MS), and thus, term of ontherapy range was used in the current study, as has been previously described. 10, 12 Liquid chromatography/tandem mass spectrometry is the gold standard method for measuring plasma DOAC levels, but DOAC levels vary widely from trough to peak among individualpatients. 13, 14 The anti-factor Xa chromogenic assay shows excellent linearity with plasma DOAC levels and is more rapid and much less expensive than LC-MS/MS 15, 16 Measurement of anti-factor Xa activity is also useful in high-risk patients, such as the elderly, and those with low body weight or low renal function. 18 However, neither LC-MS/MS nor the anti-factor Xa chromogenic assay are widely available for routine clinical testing in many laboratories.
The aims of the present study were as follows: to find an appropriate method for monitoring the anticoagulant effects of DOACs, to evaluate the correlation between anti-factor Xa activity-based plasma DOAC concentrations and the results of Apixaban We also tried to establish on-therapy ranges using conventional tests that showed strong correlations with anti-factor Xa activity-based plasma DOAC concentrations by ex vivo plasma samples. 
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| MATERIAL S AND ME THODS
| Patients and samples
| Quantification of plasma apixaban and rivaroxaban levels using the anti-factor Xa chromogenic assay
Thawed plasma samples were used. Concentrations of apixaban and rivaroxaban were determined using an anti-factor Xa chromogenic assay performed using HemosIL ® liquid anti-Xa kit (Instrumentation Laboratory, Bedford, MA), HemosIL ® apixaban calibrators and controls (Instrumentation Laboratory), and HemosIL ® rivaroxaban calibrators and controls (Instrumentation Laboratory) on an ACL TOP 700 CTS (Instrumentation Laboratory). The anti-factor Xa chromogenic assay was performed according to the manufacturer's instructions. 
| Conventional coagulation assays
| Establishing on-therapy ranges
We referred to the Clinical and Laboratory Standards Institute (CLSI) guideline H47-A2 that has been used for establishing the therapeutic range of APTT for unfractionated heparin therapy using anti-factor
Xa chromogenic assay in the clinical laboratories. 19 Relationships between plasma DOAC levels and conventional coagulation assay results significant at the P < 0.01 level were evaluated using regression 
| Statistical analysis
The analysis was performed using SPSS statistics 24 (IBM Corporation, Armonk, NY). Fisher's Exact tests for categorical variables and Mann-Whitney tests and Kruskal-Wallis tests for continuous variables were used determine the significances of differences between clinical characteristics. Pearson's correlation coefficients were used to determine levels of correlation between DOAC levels and conventional coagulation tests. Linear regression was used to establish the on-therapeutic ranges of variables.
Statistical significance was accepted for P-value of <0.01.
| RE SULTS
| Clinical characteristics of the study subjects
The clinical characteristics are summarized in Tables 1 and 2 Plasma concentrations of apixaban (P-value 0.025) and rivaroxaban (P-value 0.010) tended to increase with increasing dosages (Tables 1   and 2 ). Furthermore, the proportions of older patients and patients with higher creatinine clearance were lower among those receiving lower daily dosages of apixaban and rivaroxaban. Plasma apixaban levels were similar in patients treated or not with heparin, aspirin, and clopidogrel. The plasma concentrations of rivaroxaban showed significant difference between AF and DVT or PE patients ( Table 2 ).
| Subgroup analyses of patients administered apixaban 2.5 mg BID
Prpthrombin time (%), antithrombin, and dRVVT confirm levels were significantly correlated with plasma apixaban levels (Table 3) . 
TA B L E 4 Associations between rivaroxaban concentrations and conventional coagulation test results as determined by univariate linear regression
Weakly negative or positive linear relationships with correlations of −0.332, 0.395, and 0.367 were observed, respectively (Table   S1 ). The trough apixaban level was previously reported to be 15-83 ng/mL. 20 In the present study, established on-therapy ranges for apixaban 2.5 mg BID were 64.37%-71.17% for PT (%), 73.46%-82.09% for antithrombin, and a ratio between 1.32 and 1.52 for the dRVVT confirm test.
| Subgroup analyses of patients administered apixaban 5 mg BID
Strong correlations were observed between PT (sec), PT (%), antithrombin, dRVVT screen, and dRVVT confirm levels and plasma apixaban levels (Table 3) 
| Subgroup analyses of patients administered rivaroxaban 15 mg OD
Prothrombin time (sec), PT (%), APTT, and dRVVT confirm levels were strongly linearly correlated with plasma rivaroxaban levels ( Table 3 , Table S3 ). On-therapy ranges for rivaroxaban 15 mg OD were calculated using a previously reported trough rivaroxaban concentration range (9.42-143 ng/mL). 15 
| Subgroup analyses of patients administered rivaroxaban 20 mg OD
Strong correlations were also observed between PT (sec), PT (%), antithrombin, dRVVT screen, and dRVVT confirm levels and plasma rivaroxaban levels ( 
| Subgroup analyses of patients administered rivaroxaban 15 mg BID
Prothrombin time (sec), PT (%), dRVVT screen, and dRVVT confirm levels were strongly and linearly correlated with plasma rivaroxaban levels ( Table 4 , Table S5 ). The on-therapy range for rivaroxaban 15 
| D ISCUSS I ON
The present study was conducted at a single institution to establish on-therapy ranges for conventional coagulation assays using anti-factor Xa chromogenic assay results. PT was less sensitive to apixaban than rivaroxaban and could be within the reference range in patients with clinically relevant situations. 22, 23 Only PT (%) results were well correlated with plasma apixaban levels, whereas both PT (sec) and PT (%) results were well correlated with plasma rivaroxaban levels. However, PT does not always predictably reflect the anticoagulant activity of rivaroxaban, and the sensitivity of PT to rivaroxaban depends on the laboratory reagents used. 16, 27, 28 APTT was less sensitive to apixaban and rivaroxaban than PT, which concurs with previous reports. 24, 25 In the present study, APTT was well correlated with plasma rivaroxaban levels in patients treated with rivaroxaban ( Table 4 ). 27 Neither D-dimer nor FDP exhibited correlations with apixaban or rivaroxaban concentration.
Dilute Russell viper venom time confirm ratios were developed for the detection of lupus anticoagulant, and in the present study, they increased with plasma apixaban and rivaroxaban concentrations. In a previous study, apixaban, rivaroxaban, and dabigatran (a direct thrombin inhibitor) caused concentration-dependent prolongations of ratios of dRVVT screen and confirm tests using Diagnostica Stago ® and Haematex Reserach TM dRVVT reagents, although DOACs sometimes caused false-positive lupus anticoagulation ratios because of the use of phospholipid-rich reagents. 29, 30 In the present study, dRVVT confirm test showed strong correlations with the every group. In a previous cohort study, Diagnostica
Stago ® DRVV-confirm was found to provide a rapid estimation of the anticoagulation intensity by rivaroxaban without specific calibrators in the previous cohort study. 32, 33 Recently, the DRVV-DOAC assay was developed by Haematex Reserach TM . This assay uses a modified phospholipid-rich, liquid-stable, ready-to-use dRVVT reagent. 34 This study has limitations that deserve mention. Patients were not randomized to receive either apixaban or rivaroxaban because physicians decided on the drugs administered.Patients who received lower dosages were older and had lower creatinine clearance rates than patients who treated with higher dosages. Some patients were also concurrently treated with heparin, aspirin, and/or clopidogrel, and these treatments might have affected conventional coagulation assay results. Plasma samples were not tested for lupus anticoagulants that cause positive result in dRVVT tests. Administration periods were not considered and peak concentrations of DOACs were not measured. In this study, DOAC concentrations were measured using anti-factor Xa chromogenic assay in this study. However, quantification of low DOAC levels required the LC-MS/MS which was the gold standard method even though the linear correlation between anti-factor Xa chromogenic assay and LC-MS/MS 38 The study populations were small, and thus, we suggest a larger multi-institutional study be conducted.
In conclusion, we evaluated several conventional coagulation tests for monitoring the anticoagulant effects of DOACs. Apixaban concentrations as determined using anti-factor Xa chromogenic assay were well correlated with PT (%), antithrombin, and dRVVT confirm test in both 2.5 mg BID and 5 mg BID groups. Rivaroxaban concentrations commonly showed good correlation with PT (sec), PT (%), and dRVVT confirm test in 15 mg OD, 20 mg OD, and 15 mg BID groups. Established on-therapy ranges of each variable were summarized in Figures 1 and 2 . The present study is the first to provide on-therapy range for apixaban and rivaroxaban at meaningful clinical doses in a single institution. Although these on-therapy ranges cannot be applied on clinical practice, they could be considered in emergent situations or future studies.
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